These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

450 related items for PubMed ID: 33151508

  • 1. Diabetic ketoacidosis in patients treated with SGLT2 inhibitors: experience at a tertiary hospital.
    Papanastasiou L, Glycofridi S, Gravvanis C, Skarakis N, Papadimitriou I, Kanti G, Kapsali C, Kounadi T.
    Hormones (Athens); 2021 Jun; 20(2):369-376. PubMed ID: 33151508
    [Abstract] [Full Text] [Related]

  • 2. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
    Burke KR, Schumacher CA, Harpe SE.
    Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
    Wang L, Voss EA, Weaver J, Hester L, Yuan Z, DeFalco F, Schuemie MJ, Ryan PB, Sun D, Freedman A, Alba M, Lind J, Meininger G, Berlin JA, Rosenthal N.
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
    [Abstract] [Full Text] [Related]

  • 5. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
    Musso G, Sircana A, Saba F, Cassader M, Gambino R.
    PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Life-Threatening Complications Related to Delayed Diagnosis of Euglycemic Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Report of 2 Cases.
    Goto S, Ishikawa JY, Idei M, Iwabuchi M, Namekawa M, Nomura T.
    Am J Case Rep; 2021 Mar 16; 22():e929773. PubMed ID: 33723205
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Euglycemic diabetic ketoacidosis associated with SGLT2i use: Case series.
    Puls HA, Haas NL, Franklin BJ, Theyyunni N, Harvey CE.
    Am J Emerg Med; 2021 Jun 16; 44():11-13. PubMed ID: 33571749
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors.
    Jeon JY, Kim SK, Kim KS, Song SO, Yun JS, Kim BY, Kim CH, Park SO, Hong S, Seo DH, Seo JA, Noh JH, Kim DJ, DKA Study Group of Gyeonin Branch of the Korean Diabetes Association.
    Diabetes Metab; 2019 Oct 16; 45(5):453-457. PubMed ID: 30639566
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.